Topotecan & Product use in unapproved indication

8.8%

of users reported Product use in unapproved indication

72.4%

also reported Severe reaction

65.0%

are men

Severe reaction

72.4%

Life-threatening condition

18.4%

Death

7.1%

Hospitalization

2.0%

Topotecan: general information

0 - 9 years

38.9%

10 - 19 years

21.6%

20 - 29 years

7.2%

30 - 39 years

1.6%

40 - 49 years

1.3%

50 - 59 years

14.9%

60 - 69 years

13.0%

70 - 79 years

1.4%